Ad hoc announcement pursuant to Art. 53 LR

Q3 net sales grew +7% (cc1, +8% USD) and core operating income1 grew +7% (cc, +6% USD)
Sales growth was driven by continued strong execution on priority brands including Kisqali (+68% cc), Kesimpta (+44% cc), Pluvicto (+45% cc) and Scemblix (+95% cc)
Core operating income margin1 was stable (cc) at 39.3% despite increasing generic impact
Q3 operating income grew +27% (cc, +24% USD); net income rose +25% (cc, +23% USD)
Q3 core EPS1 grew +10% (cc, +9% USD) to USD 2.25
Q3 free cash flow1 was USD 6.2 billion (+4% USD) driven by higher net cash flows from operating activities
Strong nine months performance with net sales up +11% (cc, +11% USD) and core operating income up +18% (cc, +16% USD)
Q3 selected innovation milestones:
Rhapsido FDA approval as the only oral, targeted BTK inhibitor for CSU
Ianalumab positive replicate Phase III readouts in Sjogren’s disease
Pluvicto positive Phase III PSMAddition data at ESMO
Scemblix positive CHMP opinion for all lines of CML treatment
Cosentyx positive Phase III readout in PMR
Fabhalta positive Phase III eGFR readout in IgA nephropathy
Full-year 2025 guidance2 reaffirmed
Sales expected to grow high single-digit
Core operating income expected to grow low-teens
1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 42 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year. 2. Please see detailed guidance assumptions on page 7.

Basel, October 28, 2025 – Commenting on Q3 2025 results, Vas Narasimhan, CEO of Novartis, said:
“Novartis delivered solid financial performance in Q3, more than offsetting the impact of increasing generic erosion in the US. Our key growth drivers performed well, including Kisqali, Kesimpta, Pluvicto and Scemblix. Importantly, we achieved FDA approval for Rhapsido in CSU and positive Phase III readouts for ianalumab in Sjogren’s disease – two assets with pipeline-in-a-pill potential that could underpin our growth through 2030 and beyond. In addition, we completed several deals in the quarter to further strengthen our pipeline in core therapeutic areas. We remain well on track to achieve our guidance for 2025 and over the mid-term."

Key figures see & read more on
https://www.novartis.com/news/media-releases/novartis-delivers-solid-sales-and-core-operating-income-growth-strong-pipeline-progress-q3-reaffirms-fy-2025-guidance